-
1
-
-
0032554527
-
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
-
Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri D. 1998. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882-883.
-
(1998)
Lancet
, vol.351
, pp. 882-883
-
-
Adida, C.1
Berrebi, D.2
Peuchmaur, M.3
Reyes-Mugica, M.4
Altieri, D.5
-
2
-
-
0036791008
-
p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene
-
Adimoolam S, Ford JM. 2002. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 99:12985-12990.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 12985-12990
-
-
Adimoolam, S.1
Ford, J.M.2
-
3
-
-
0032521205
-
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
-
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr. 1998. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149-1158.
-
(1998)
Cancer Res
, vol.58
, pp. 1149-1158
-
-
Ahnen, D.J.1
Feigl, P.2
Quan, G.3
Fenoglio-Preiser, C.4
Lovato, L.C.5
Bunn Jr., P.A.6
Stemmerman, G.7
Wells, J.D.8
Macdonald, J.S.9
Meyskens Jr., F.L.10
-
4
-
-
0033595018
-
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array
-
Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D. 1999. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA 96:7382-7387.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 7382-7387
-
-
Ahrendt, S.A.1
Halachmi, S.2
Chow, J.T.3
Wu, L.4
Halachmi, N.5
Yang, S.C.6
Wehage, S.7
Jen, J.8
Sidransky, D.9
-
5
-
-
1642398622
-
Interpretation of p53 immunoreactivity in endometrial carcinoma: Establishing a clinically relevant cut-off level
-
Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. 2004. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level, Int J Gynecol Pathol 23:129-137.
-
(2004)
Int J Gynecol Pathol
, vol.23
, pp. 129-137
-
-
Alkushi, A.1
Lim, P.2
Coldman, A.3
Huntsman, D.4
Miller, D.5
Gilks, C.B.6
-
6
-
-
0032735232
-
Survivin apoptosis: An interloper between cell death and cell proliferation in cancer
-
Altieri DC, Marchisio C. 1999. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327-1333.
-
(1999)
Lab Invest
, vol.79
, pp. 1327-1333
-
-
Altieri, D.C.1
Marchisio, C.2
-
7
-
-
0030746636
-
A novel anti-apoptotic gene, survivin, expressed in cancer and lymphoma
-
Ambrosini G, Adida C, Altieri DC. 1997. A novel anti-apoptotic gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
-
(1997)
Nat Med
, vol.3
, pp. 917-921
-
-
Ambrosini, G.1
Adida, C.2
Altieri, D.C.3
-
8
-
-
0031984809
-
Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression
-
Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC. 1998. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 58:334-341.
-
(1998)
Cancer Res
, vol.58
, pp. 334-341
-
-
Ambs, S.1
Merriam, W.G.2
Bennett, W.P.3
Felley-Bosco, E.4
Ogunfusika, M.O.5
Oser, S.M.6
Klein, S.7
Shields, P.G.8
Billiar, T.R.9
Harris, C.C.10
-
9
-
-
0032508504
-
Enhanced phosphorylation of p53 by ATM in response to DNA damage
-
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677.
-
(1998)
Science
, vol.281
, pp. 1674-1677
-
-
Banin, S.1
Moyal, L.2
Shieh, S.3
Taya, Y.4
Anderson, C.W.5
Chessa, L.6
Smorodinsky, N.I.7
Prives, C.8
Reiss, Y.9
Shiloh, Y.10
Ziv, Y.11
-
10
-
-
1842737710
-
A global suppressor motif for p53 cancer mutants
-
Baroni TE, Wang T, Qian II, Dearth LH, Truong LN, Zeng J, Denes AE, Chen SW, Brachmann RK. 2004. A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci USA 101:4930-4935.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 4930-4935
-
-
Baroni, T.E.1
Wang, T.2
Qian, I.I.3
Dearth, L.H.4
Truong, L.N.5
Zeng, J.6
Denes, A.E.7
Chen, S.W.8
Brachmann, R.K.9
-
11
-
-
0038418869
-
Chk1 and Chk2 kinases in checkpoint control and cancer
-
Bartek J, Lukas J. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429.
-
(2003)
Cancer Cell
, vol.3
, pp. 421-429
-
-
Bartek, J.1
Lukas, J.2
-
12
-
-
0036094195
-
A phase I/pilot study of sequential doxorubicin/vinorelbine: Effects on p53 and microtubule-associated protein 4
-
Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon B, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN. 2002. A phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res 8:1057-1064.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1057-1064
-
-
Bash-Babula, J.1
Toppmeyer, D.2
Labassi, M.3
Reidy, J.4
Orlick, M.5
Senzon, B.6
Alli, E.7
Kearney, T.8
August, D.9
Shih, W.10
Yang, J.M.11
Hait, W.N.12
-
13
-
-
0028339379
-
Is p53 polymorphism maintained by natural selection?
-
Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. 1994. Is p53 polymorphism maintained by natural selection? Hum Hered 44:266-270.
-
(1994)
Hum Hered
, vol.44
, pp. 266-270
-
-
Beckman, G.1
Birgander, R.2
Sjalander, A.3
Saha, N.4
Holmberg, P.A.5
Kivela, A.6
Beckman, L.7
-
14
-
-
10744230945
-
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
-
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico C, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402.
-
(2003)
Cancer Cell
, vol.3
, pp. 387-402
-
-
Bergamaschi, D.1
Gasco, M.2
Hiller, L.3
Sullivan, A.4
Syed, N.5
Trigiante, G.6
Yulug, I.7
Merlano, M.8
Numico, C.9
Comino, A.10
Attard, M.11
Reelfs, O.12
Gusterson, B.13
Bell, A.K.14
Heath, V.15
Tavassoli, M.16
Farrell, P.J.17
Smith, P.18
Lu, X.19
Crook, T.20
more..
-
15
-
-
0037220165
-
The UMD-p53 database: New mutations and analysis tools
-
Berond C, Soussi T. 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176-181.
-
(2003)
Hum Mutat
, vol.21
, pp. 176-181
-
-
Berond, C.1
Soussi, T.2
-
16
-
-
0033552948
-
Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
-
Blandino G, Levine AJ, Oren M. 1999. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485.
-
(1999)
Oncogene
, vol.18
, pp. 477-485
-
-
Blandino, G.1
Levine, A.J.2
Oren, M.3
-
17
-
-
3042838562
-
Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine
-
Block WD, Merkle D, Meek K, Lees-Miller SP. 2004. Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine. Nucleic Acids Res 32:1967-1972.
-
(2004)
Nucleic Acids Res
, vol.32
, pp. 1967-1972
-
-
Block, W.D.1
Merkle, D.2
Meek, K.3
Lees-Miller, S.P.4
-
18
-
-
10744224153
-
Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients
-
Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci C, Olivieri F, Franceschi C. 2003. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9:4860-4864.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 4860-4864
-
-
Bonafe, M.1
Ceccarelli, C.2
Farabegoli, F.3
Santini, D.4
Taffurelli, M.5
Barbi, C.6
Marzi, E.7
Trapassi, C.8
Storci, C.9
Olivieri, F.10
Franceschi, C.11
-
19
-
-
0031929626
-
TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival
-
Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. 1998. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 203-210
-
-
Borresen-Dale, A.L.1
Lothe, R.A.2
Meling, G.I.3
Hainaut, P.4
Rognum, T.O.5
Skovlund, E.6
-
20
-
-
0034674901
-
A family of drug transporters: The multidrug resistance-associated proteins
-
Borst P, Evers R, Kool M, Wijnholds J. 2000. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 1295-1302
-
-
Borst, P.1
Evers, R.2
Kool, M.3
Wijnholds, J.4
-
21
-
-
0033926876
-
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
-
Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L. 2000. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6:2751-2758.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2751-2758
-
-
Bottini, A.1
Berruti, A.2
Bersiga, A.3
Brizzi, M.P.4
Brunelli, A.5
Gorzegno, G.6
DiMarco, B.7
Aguggini, S.8
Bolsi, G.9
Cirillo, F.10
Filippini, L.11
Betri, E.12
Bertoli, G.13
Alquati, P.14
Dogliotti, L.15
-
22
-
-
0041342137
-
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines
-
Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE, 2003. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25:654-661.
-
(2003)
Head Neck
, vol.25
, pp. 654-661
-
-
Bradford, C.R.1
Zhu, S.2
Ogawa, H.3
Ogawa, T.4
Ubell, M.5
Narayan, A.6
Johnson, G.7
Wolf, G.T.8
Fisher, S.G.9
Carey, T.E.10
-
23
-
-
0025719491
-
A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma
-
Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. 1991. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 88:10124-10128.
-
(1991)
Proc Natl Acad Sci U S A
, vol.88
, pp. 10124-10128
-
-
Brash, D.E.1
Rudolph, J.A.2
Simon, J.A.3
Lin, A.4
McKenna, G.J.5
Baden, H.P.6
Halperin, A.J.7
Ponten, J.8
-
24
-
-
0034671556
-
Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus
-
Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin WG Jr, Crook T. 2000. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60:6875-6877.
-
(2000)
Cancer Res
, vol.60
, pp. 6875-6877
-
-
Brooks, L.A.1
Tidy, J.A.2
Gusterson, B.3
Hiller, L.4
O'Nions, J.5
Gasco, M.6
Marin, M.C.7
Farrell, P.J.8
Kaelin Jr., W.G.9
Crook, T.10
-
25
-
-
0023709002
-
A variation in the structure of the protein-coding region of the human p53 gene
-
Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. 1988. A variation in the structure of the protein-coding region of the human p53 gene. Gene 70:245-252.
-
(1988)
Gene
, vol.70
, pp. 245-252
-
-
Buchman, V.L.1
Chumakov, P.M.2
Ninkina, N.N.3
Samarina, O.P.4
Georgiev, G.P.5
-
26
-
-
8444232549
-
The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer
-
Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. 2004. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22:86-96.
-
(2004)
J Clin Oncol
, vol.22
, pp. 86-96
-
-
Bull, S.B.1
Ozcelik, H.2
Pinnaduwage, D.3
Blackstein, M.E.4
Sutherland, D.A.5
Pritchard, K.I.6
Tzontcheva, A.T.7
Sidlofsky, S.8
Hanna, W.M.9
Qizilbash, A.H.10
Tweeddale, M.E.11
Fine, S.12
McCready, D.R.13
Andrulis, I.L.14
-
27
-
-
0033546182
-
DNA-dependent protein kinase-independent activation of p53 in response to DNA damage
-
Burma S, Kurimasa A, Xie G, Taya Y, Araki R, Abe M, Crissman HA, Ouyang H, Li G. C, Chen DJ. 1999. DNA-dependent protein kinase-independent activation of p53 in response to DNA damage. J Biol Chem 274:171139-17143.
-
(1999)
J Biol Chem
, vol.274
, pp. 171139-117143
-
-
Burma, S.1
Kurimasa, A.2
Xie, G.3
Taya, Y.4
Araki, R.5
Abe, M.6
Crissman, H.A.7
Ouyang, H.8
Li, G.C.9
Chen, D.J.10
-
28
-
-
0036128899
-
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
-
Bykov VJ, Issaeva N, Shilov A, Hulterantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288.
-
(2002)
Nat Med
, vol.8
, pp. 282-288
-
-
Bykov, V.J.1
Issaeva, N.2
Shilov, A.3
Hulterantz, M.4
Pugacheva, E.5
Chumakov, P.6
Bergman, J.7
Wiman, K.G.8
Selivanova, G.9
-
30
-
-
0035904394
-
The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth
-
Cadwell C, Zambetti GP. 2001. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30.
-
(2001)
Gene
, vol.277
, pp. 15-30
-
-
Cadwell, C.1
Zambetti, G.P.2
-
31
-
-
1842509884
-
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma
-
Chatterjee SJ, Datar R, Yonssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. 2004. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22:1007-1013.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1007-1013
-
-
Chatterjee, S.J.1
Datar, R.2
Yonssefzadeh, D.3
George, B.4
Goebell, P.J.5
Stein, J.P.6
Young, L.7
Shi, S.R.8
Gee, C.9
Groshen, S.10
Skinner, D.G.11
Cote, R.J.12
-
32
-
-
0037317840
-
Inhibiting the p53-MDM2 interaction: An important target for cancer therapy
-
Chene P. 2003. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev Cancer 3:102-109.
-
(2003)
Nature Rev Cancer
, vol.3
, pp. 102-109
-
-
Chene, P.1
-
33
-
-
0031427453
-
Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy
-
Chevillard S, Lebeau J, Pouillart P, de Toma C, Beldjord C, Asselain B, Klijanienko J, Fourquet A, Magdelenat H, Vielh P. 1997. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471-2478.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 2471-2478
-
-
Chevillard, S.1
Lebeau, J.2
Pouillart, P.3
De Toma, C.4
Beldjord, C.5
Asselain, B.6
Klijanienko, J.7
Fourquet, A.8
Magdelenat, H.9
Vielh, P.10
-
34
-
-
0027983669
-
Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
-
Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
-
(1994)
Science
, vol.265
, pp. 346-355
-
-
Cho, Y.1
Gorina, S.2
Jeffrey, P.D.3
Pavletich, N.P.4
-
35
-
-
0037326291
-
Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells
-
Choi KS, Lee TH, Jung MH. 2003. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 10:87-95.
-
(2003)
Cancer Gene Ther
, vol.10
, pp. 87-95
-
-
Choi, K.S.1
Lee, T.H.2
Jung, M.H.3
-
36
-
-
0031919283
-
p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
-
Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ. 1998. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16:470-479.
-
(1998)
J Clin Oncol
, vol.16
, pp. 470-479
-
-
Clahsen, P.C.1
Van De Velde, C.J.2
Duval, C.3
Pallud, C.4
Mandard, A.M.5
Delobelle-Deroide, A.6
Van Den Broek, L.7
Sahmoud, T.M.8
Van De Vijver, M.J.9
-
37
-
-
1542299064
-
Evaluation of oligonucleotide arrays for sequencing of the p53 gene in DNA from formalin-fixed, paraffin-embedded breast cancer specimens
-
Cooper M, Li SQ, Bhardwaj T, Rohan T, Kandel RA. 2004. Evaluation of oligonucleotide arrays for sequencing of the p53 gene in DNA from formalin-fixed, paraffin-embedded breast cancer specimens. Clin Chem 50:500-508.
-
(2004)
Clin Chem
, vol.50
, pp. 500-508
-
-
Cooper, M.1
Li, S.Q.2
Bhardwaj, T.3
Rohan, T.4
Kandel, R.A.5
-
38
-
-
0027210981
-
Gain of function mutations in p53
-
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Lexine AJ. 1993. Gain of function mutations in p53. Nat Genet 4:42-46.
-
(1993)
Nat Genet
, vol.4
, pp. 42-46
-
-
Dittmer, D.1
Pati, S.2
Zambetti, G.3
Chu, S.4
Teresky, A.K.5
Moore, M.6
Finlay, C.7
Lexine, A.J.8
-
39
-
-
0345256634
-
The role of p53 in chemosensitivity and radiosensitivity
-
El-Deiry WS. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495.
-
(2003)
Oncogene
, vol.22
, pp. 7486-7495
-
-
El-Deiry, W.S.1
-
40
-
-
1242297013
-
Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder
-
El-Kenawy A-M, El-Kott AF, Khalil AM. 2003. Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder. Int J Biol Markers 18:284-289.
-
(2003)
Int J Biol Markers
, vol.18
, pp. 284-289
-
-
El-Kenawy, A.-M.1
El-Kott, A.F.2
Khalil, A.M.3
-
41
-
-
0029155714
-
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer
-
Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, et al. 1995. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256.
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 1254-1256
-
-
Elledge, R.M.1
Gray, R.2
Mansour, E.3
Yu, Y.4
Clark, G.M.5
Ravdin, P.6
Osborne, C.K.7
Gilchrist, K.8
Davidson, N.E.9
Robert, N.10
-
42
-
-
0034254821
-
Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?
-
Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B. 2000. Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 56:239-244.
-
(2000)
Radiother Oncol
, vol.56
, pp. 239-244
-
-
Elsaleh, H.1
Robbins, P.2
Joseph, D.3
Powell, B.4
Grieu, F.5
Menso, L.6
Iacopetta, B.7
-
43
-
-
0032473823
-
TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer
-
Erber B, Conradt C, Homann N, Enders C, Finekh M, Dietz A, Weidauer H, Bosch FX. 1998. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679.
-
(1998)
Oncogene
, vol.16
, pp. 1671-1679
-
-
Erber, B.1
Conradt, C.2
Homann, N.3
Enders, C.4
Finekh, M.5
Dietz, A.6
Weidauer, H.7
Bosch, F.X.8
-
44
-
-
0025312728
-
A genetic model for colorectal tumorigenesis
-
Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
-
(1990)
Cell
, vol.61
, pp. 759-767
-
-
Fearon, E.R.1
Vogelstein, B.2
-
45
-
-
0037152679
-
Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2
-
Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D. 2002. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer 87:1027-1033.
-
(2002)
Br J Cancer
, vol.87
, pp. 1027-1033
-
-
Fedier, A.1
Ruefenacht, U.B.2
Schwarz, V.A.3
Haller, U.4
Fink, D.5
-
46
-
-
3142675287
-
p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase
-
Fedier A, Moawad A, Haller U, Fink D. 2003a. p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase. Int J Oncol 23:1431-1437.
-
(2003)
Int J Oncol
, vol.23
, pp. 1431-1437
-
-
Fedier, A.1
Moawad, A.2
Haller, U.3
Fink, D.4
-
47
-
-
0038011619
-
Loss of arm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites
-
Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. 2003b. Loss of arm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol 14:938-945.
-
(2003)
Ann Oncol
, vol.14
, pp. 938-945
-
-
Fedier, A.1
Schlamminger, M.2
Schwarz, V.A.3
Haller, U.4
Howell, S.B.5
Fink, D.6
-
48
-
-
0043130465
-
The effect of loss of Brea1 on the sensitivity to anticancer agents in p53-deficient cells
-
Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. 2003c. The effect of loss of Brea1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 22:1169-1173.
-
(2003)
Int J Oncol
, vol.22
, pp. 1169-1173
-
-
Fedier, A.1
Steiner, R.A.2
Schwarz, V.A.3
Lenherr, L.4
Haller, U.5
Fink, D.6
-
50
-
-
0036269099
-
Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer
-
Fernebro E, Dictor M, Bendahl PO, Ferno M, Nilbert M. 2002. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126:702-705.
-
(2002)
Arch Pathol Lab Med
, vol.126
, pp. 702-705
-
-
Fernebro, E.1
Dictor, M.2
Bendahl, P.O.3
Ferno, M.4
Nilbert, M.5
-
52
-
-
0842265105
-
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer
-
Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, Pera M. 2004. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206-215.
-
(2004)
Br J Cancer
, vol.90
, pp. 206-215
-
-
Fondevila, C.1
Metges, J.P.2
Fuster, J.3
Grau, J.J.4
Palacin, A.5
Castells, A.6
Volant, A.7
Pera, M.8
-
53
-
-
0033601370
-
Pharmacological rescue of mutant p53 conformation and function
-
Foster BA, Coffey HA, Morin MJ, Rastinejad F. 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510.
-
(1999)
Science
, vol.286
, pp. 2507-2510
-
-
Foster, B.A.1
Coffey, H.A.2
Morin, M.J.3
Rastinejad, F.4
-
54
-
-
0037154149
-
A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants
-
Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR. 2002. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99:937-942.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 937-942
-
-
Friedler, A.1
Hansson, L.O.2
Veprintsev, D.B.3
Freund, S.M.4
Rippin, T.M.5
Nikolova, P.V.6
Proctor, M.R.7
Rudiger, S.8
Fersht, A.R.9
-
55
-
-
0036094242
-
p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract
-
Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T. 2002. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8:1192-1195.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1192-1195
-
-
Furihata, M.1
Takeuchi, T.2
Matsumoto, M.3
Kurabayashi, A.4
Ohtsuki, Y.5
Terao, N.6
Kuwahara, M.7
Shuin, T.8
-
56
-
-
0344198117
-
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer
-
Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE. 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9:5582-5588.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 5582-5588
-
-
Geisler, S.1
Borresen-Dale, A.L.2
Johnsen, H.3
Aas, T.4
Geisler, J.5
Akslen, L.A.6
Anker, G.7
Lonning, P.E.8
-
57
-
-
0037303255
-
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-Year follow up data
-
Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD. 2003. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97:527-536.
-
(2003)
Cancer
, vol.97
, pp. 527-536
-
-
Goffin, J.R.1
Chappuis, P.O.2
Begin, L.R.3
Wong, N.4
Brunet, J.S.5
Hamel, N.6
Paradis, A.J.7
Boyd, J.8
Foulkes, W.D.9
-
58
-
-
0028939453
-
Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line
-
Goldsmith ME, Gridas JM, Schneider E, Cowan KH. 1995. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem. 270:1894-1898.
-
(1995)
J Biol Chem
, vol.270
, pp. 1894-1898
-
-
Goldsmith, M.E.1
Gridas, J.M.2
Schneider, E.3
Cowan, K.H.4
-
60
-
-
0346362405
-
Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx
-
Griffin MC, Robinson RA, Trask DK. 2003. Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol 16:1181-1188.
-
(2003)
Mod Pathol
, vol.16
, pp. 1181-1188
-
-
Griffin, M.C.1
Robinson, R.A.2
Trask, D.K.3
-
61
-
-
0033397882
-
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma
-
Grossman D, McNiff JM, Li F, Altieri DC. 1999. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081.
-
(1999)
J Invest Dermatol
, vol.113
, pp. 1076-1081
-
-
Grossman, D.1
McNiff, J.M.2
Li, F.3
Altieri, D.C.4
-
62
-
-
0034795822
-
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53
-
Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC. 2001. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 108:991-999.
-
(2001)
J Clin Invest
, vol.108
, pp. 991-999
-
-
Grossman, D.1
Kim, P.J.2
Blanc-Brude, O.P.3
Brash, D.E.4
Tognin, S.5
Marchisio, P.C.6
Altieri, D.C.7
-
63
-
-
0037317521
-
The role of p53 in determining sensitivity to radiotherapy
-
Gudkov AV, Komarova EA. 2003. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117-129.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 117-129
-
-
Gudkov, A.V.1
Komarova, E.A.2
-
64
-
-
0034295214
-
Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance
-
Guo-Chang F, Chu-Tse W. 2000. Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance. Cancer Lett 158:203-210.
-
(2000)
Cancer Lett
, vol.158
, pp. 203-210
-
-
Guo-Chang, F.1
Chu-Tse, W.2
-
65
-
-
0032990031
-
Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
-
Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. 1999. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 44:143-151.
-
(1999)
Cancer Chemother Pharmacol
, vol.44
, pp. 143-151
-
-
Gurnani, M.1
Lipari, P.2
Dell, J.3
Shi, B.4
Nielsen, L.L.5
-
66
-
-
0033992478
-
p53 and human cancer: The first ten thousand mutations
-
Hainaut P, Hollstein M. 2000. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137.
-
(2000)
Adv Cancer Res
, vol.77
, pp. 81-137
-
-
Hainaut, P.1
Hollstein, M.2
-
67
-
-
0038824021
-
Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers
-
Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M. 2003. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 94:394-399.
-
(2003)
Cancer Sci
, vol.94
, pp. 394-399
-
-
Harada, T.1
Ogura, S.2
Yamazaki, K.3
Kinoshita, I.4
Itoh, T.5
Isobe, H.6
Yamashiro, K.7
Dosaka-Akita, H.8
Nishimura, M.9
-
68
-
-
0028842340
-
A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice
-
Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9:305-311.
-
(1995)
Nat Genet
, vol.9
, pp. 305-311
-
-
Harvey, M.1
Vogel, H.2
Morris, D.3
Bradley, A.4
Bernstein, A.5
Donehower, L.A.6
-
69
-
-
0242486786
-
Detection of p53 gene mutations by nonisotopic RNase cleavage assay as a predictor of poor prognosis in colorectal cancers
-
Haseba M, Hidaka S, Tsuji T, Yano H, Komatsu H, Sawai T, Yasutake T, Nakagoe T, Tagawa Y, Ayabe H. 2003. Detection of p53 gene mutations by nonisotopic RNase cleavage assay as a predictor of poor prognosis in colorectal cancers. Dig Dis Sci 48:1984-1989.
-
(2003)
Dig Dis Sci
, vol.48
, pp. 1984-1989
-
-
Haseba, M.1
Hidaka, S.2
Tsuji, T.3
Yano, H.4
Komatsu, H.5
Sawai, T.6
Yasutake, T.7
Nakagoe, T.8
Tagawa, Y.9
Ayabe, H.10
-
70
-
-
0033229836
-
p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas
-
Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E. 1999. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59:5572-5577.
-
(1999)
Cancer Res
, vol.59
, pp. 5572-5577
-
-
Hashimoto, T.1
Tokuchi, Y.2
Hayashi, M.3
Kobayashi, Y.4
Nishida, K.5
Hayashi, S.6
Ishikawa, Y.7
Tsuchiya, S.8
Nakagawa, K.9
Hayashi, J.10
Tsuchiya, E.11
-
71
-
-
0030905284
-
Mdm2 promotes the rapid degradation of p53
-
Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
-
(1997)
Nature
, vol.387
, pp. 296-299
-
-
Haupt, Y.1
Maya, R.2
Kazaz, A.3
Oren, M.4
-
72
-
-
0037441760
-
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
-
Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chanhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. 2003. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534.
-
(2003)
Blood
, vol.101
, pp. 1530-1534
-
-
Hideshima, T.1
Mitsiades, C.2
Akiyama, M.3
Hayashi, T.4
Chanhan, D.5
Richardson, P.6
Schlossman, R.7
Podar, K.8
Munshi, N.C.9
Mitsiades, N.10
Anderson, K.C.11
-
73
-
-
0034629072
-
DNA damage-induced activation of p53 by the checkpoint kinase Chk2
-
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW. 2000. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824-1827.
-
(2000)
Science
, vol.287
, pp. 1824-1827
-
-
Hirao, A.1
Kong, Y.Y.2
Matsuoka, S.3
Wakeham, A.4
Ruland, J.5
Yoshida, H.6
Liu, D.7
Elledge, S.J.8
Mak, T.W.9
-
74
-
-
0036479115
-
Transcriptional repression of the anti-apoptotic survivin gene by wild type p53
-
Hoffman WH, Biade S, Zilfon JT, Chen J, Murphy M. 2002. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257.
-
(2002)
J Biol Chem
, vol.277
, pp. 3247-3257
-
-
Hoffman, W.H.1
Biade, S.2
Zilfon, J.T.3
Chen, J.4
Murphy, M.5
-
76
-
-
0033521621
-
Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
-
Honda R, Yasuda H. 1999. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22-27.
-
(1999)
EMBO J
, vol.18
, pp. 22-27
-
-
Honda, R.1
Yasuda, H.2
-
77
-
-
0031583962
-
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
-
Honda K, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-27.
-
(1997)
FEBS Lett
, vol.420
, pp. 25-27
-
-
Honda, K.1
Tanaka, H.2
Yasuda, H.3
-
78
-
-
0041997348
-
Chemosensitivity linked to p73 function
-
Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr. 2003. Chemosensitivity linked to p73 function. Cancer Cell 3:403-410.
-
(2003)
Cancer Cell
, vol.3
, pp. 403-410
-
-
Irwin, M.S.1
Kondo, K.2
Marin, M.C.3
Cheng, L.S.4
Hahn, W.C.5
Kaelin Jr., W.G.6
-
79
-
-
0345255605
-
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
-
Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. 2003. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 100:13303-13307.
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 13303-13307
-
-
Issaeva, N.1
Friedler, A.2
Bozko, P.3
Wiman, K.G.4
Fersht, A.R.5
Selivanova, G.6
-
80
-
-
0030036839
-
Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas
-
Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S. 1996. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69:236-240.
-
(1996)
Int J Cancer
, vol.69
, pp. 236-240
-
-
Iwadate, Y.1
Fujimoto, S.2
Tagawa, M.3
Namba, H.4
Sueyoshi, K.5
Hirose, M.6
Sakiyama, S.7
-
81
-
-
0033958086
-
Multiple physiological functions for multidrug transporter P-glycoprotein?
-
Johnstone RW, Ruefli AA, Smyth MJ. 2000. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25:1-6.
-
(2000)
Trends Biochem Sci
, vol.25
, pp. 1-6
-
-
Johnstone, R.W.1
Ruefli, A.A.2
Smyth, M.J.3
-
82
-
-
0034324572
-
UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells
-
Jones CB, Clements MK, Redkar A, Daoud SS. 2000. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells. Int J Oncol 17:1043-1051.
-
(2000)
Int J Oncol
, vol.17
, pp. 1043-1051
-
-
Jones, C.B.1
Clements, M.K.2
Redkar, A.3
Daoud, S.S.4
-
83
-
-
0042856237
-
Tissue microarray technology: Validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression
-
Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, Duval A, Hamelin R, Flejou JF. 2003. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443:115-121.
-
(2003)
Virchows Arch
, vol.443
, pp. 115-121
-
-
Jourdan, F.1
Sebbagh, N.2
Comperat, E.3
Mourra, N.4
Flahault, A.5
Olschwang, S.6
Duval, A.7
Hamelin, R.8
Flejou, J.F.9
-
84
-
-
0027501841
-
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene
-
Juven T, Barak Y, Zauberman A, George DL, Oren M. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
-
(1993)
Oncogene
, vol.8
, pp. 3411-3416
-
-
Juven, T.1
Barak, Y.2
Zauberman, A.3
George, D.L.4
Oren, M.5
-
85
-
-
0035138823
-
p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent
-
Kemp CJ, Sun S, Gurley KE. 2001. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res 61:327-332.
-
(2001)
Cancer Res
, vol.61
, pp. 327-332
-
-
Kemp, C.J.1
Sun, S.2
Gurley, K.E.3
-
86
-
-
0033646912
-
p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma
-
Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP. 2000. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 35:563-568.
-
(2000)
Med Pediatr Oncol
, vol.35
, pp. 563-568
-
-
Keshelava, N.1
Zuo, J.J.2
Waidyaratne, N.S.3
Triche, T.J.4
Reynolds, C.P.5
-
87
-
-
0041833667
-
Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53
-
Keshelava N, Tsao-Wei D, Reynolds CP. 2003. Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res 9:3492-3502.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 3492-3502
-
-
Keshelava, N.1
Tsao-Wei, D.2
Reynolds, C.P.3
-
88
-
-
0028057398
-
High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer
-
Khine K, Smith DR, Goh HS. 1994. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer 73:28-35.
-
(1994)
Cancer
, vol.73
, pp. 28-35
-
-
Khine, K.1
Smith, D.R.2
Goh, H.S.3
-
89
-
-
0031031049
-
Tumors associated with p53 germline mutations: A synopsis of 91 families
-
Kleihnes P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. 1997. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150:1-13.
-
(1997)
Am J Pathol
, vol.150
, pp. 1-13
-
-
Kleihnes, P.1
Schauble, B.2
Zur Hausen, A.3
Esteve, J.4
Ohgaki, H.5
-
90
-
-
0034108062
-
Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer
-
Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K. 2000. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 91:416-423.
-
(2000)
Jpn J Cancer Res
, vol.91
, pp. 416-423
-
-
Koga, F.1
Kitahara, S.2
Arai, K.3
Honda, M.4
Sumi, S.5
Yoshida, K.6
-
91
-
-
0035829685
-
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
-
Komaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. 2001. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20:7453-7463.
-
(2001)
Oncogene
, vol.20
, pp. 7453-7463
-
-
Komaras, K.1
Cuddihy, A.R.2
Christopoulos, H.3
Hogg, A.4
O'Connell, M.J.5
-
92
-
-
0033105876
-
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
-
Austrian Breast Cancer Study Group
-
Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlbock M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R. 1999. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 35:398-405.
-
(1999)
Eur J Cancer
, vol.35
, pp. 398-405
-
-
Kucera, E.1
Speiser, P.2
Gnant, M.3
Szabo, L.4
Samonigg, H.5
Hausmaninger, H.6
Mittlbock, M.7
Fridrik, M.8
Seifert, M.9
Kubista, E.10
Reiner, A.11
Zeillinger, R.12
Jakesz, R.13
-
93
-
-
0942301261
-
Spectrum of p53 tumor suppressor gene mutations and breast cancer survival
-
Lai H, Ma F, Trapido E, Meng L, Lai S. 2004. Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. Breast Cancer Res Treat 83:57-66.
-
(2004)
Breast Cancer Res Treat
, vol.83
, pp. 57-66
-
-
Lai, H.1
Ma, F.2
Trapido, E.3
Meng, L.4
Lai, S.5
-
94
-
-
18744406282
-
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 antoubiquitination activity by small molecular weight inhibitors
-
Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P, Rolfe M, Caligiuri VI, Benfield PA, Auger KR, Copeland RA. 2002. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 antoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 99:14734-14739.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 14734-14739
-
-
Lai, Z.1
Yang, T.2
Kim, Y.B.3
Sielecki, T.M.4
Diamond, M.A.5
Strack, P.6
Rolfe, M.7
Caligiuri, V.I.8
Benfield, P.A.9
Auger, K.R.10
Copeland, R.A.11
-
96
-
-
0742317835
-
Distinct subtypes of serous ovarian carcinoma identified by p53 determination
-
Lassus H, Leminen A, Luudin J, Lehtovirta P, Butzow R. 2003. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91:504-512.
-
(2003)
Gynecol Oncol
, vol.91
, pp. 504-512
-
-
Lassus, H.1
Leminen, A.2
Luudin, J.3
Lehtovirta, P.4
Butzow, R.5
-
97
-
-
0142092681
-
Prognostic significance of Bcl-2 and p53 expression in gastric cancer
-
Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. 2003. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis 18:518-525.
-
(2003)
Int J Colorectal Dis
, vol.18
, pp. 518-525
-
-
Lee, H.K.1
Lee, H.S.2
Yang, H.K.3
Kim, W.H.4
Lee, K.U.5
Choe, K.J.6
Kim, J.P.7
-
98
-
-
0042023334
-
Expression of p53, pRB, and p16 in lung tumours: A validation study on tissue microarravs
-
Leversha MA, Fielding P, Watson S, Gosney JR, Field JK. 2003. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarravs. J Pathol 200:610-619.
-
(2003)
J Pathol
, vol.200
, pp. 610-619
-
-
Leversha, M.A.1
Fielding, P.2
Watson, S.3
Gosney, J.R.4
Field, J.K.5
-
99
-
-
0031691792
-
Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value
-
Levesque MA, D'Costa M, Spratt EH, Yaman MM, Diamandis EP. 1998. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. Int J Cancer 79:494-501.
-
(1998)
Int J Cancer
, vol.79
, pp. 494-501
-
-
Levesque, M.A.1
D'Costa, M.2
Spratt, E.H.3
Yaman, M.M.4
Diamandis, E.P.5
-
100
-
-
0036466874
-
p53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
-
Liang J-T, Huang K-C, Cheng Y-M, Hsu H-C, Cheng A-L, Hsu C-H, Yeb K-H, Wang S-M, Chang K-J. 2002. p53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 97:451-457.
-
(2002)
Int J Cancer
, vol.97
, pp. 451-457
-
-
Liang, J.-T.1
Huang, K.-C.2
Cheng, Y.-M.3
Hsu, H.-C.4
Cheng, A.-L.5
Hsu, C.-H.6
Yeb, K.-H.7
Wang, S.-M.8
Chang, K.-J.9
-
101
-
-
0035866361
-
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin
-
Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. 2001. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 61:1508-1516.
-
(2001)
Cancer Res
, vol.61
, pp. 1508-1516
-
-
Lin, X.1
Ramamurthi, K.2
Mishima, M.3
Kondo, A.4
Christen, R.D.5
Howell, S.B.6
-
102
-
-
1042299134
-
Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer
-
Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian, S. 2004. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 198:83-90.
-
(2004)
J Am Coll Surg
, vol.198
, pp. 83-90
-
-
Linjawi, A.1
Kontogiannea, M.2
Halwani, F.3
Edwardes, M.4
Meterissian, S.5
-
103
-
-
0030015546
-
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer
-
Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. 1996. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74:63-68.
-
(1996)
Br J Cancer
, vol.74
, pp. 63-68
-
-
Linn, S.C.1
Honkoop, A.H.2
Hoekman, K.3
Van Der Valk, P.4
Pinedo, H.M.5
Giaccone, G.6
-
104
-
-
0030986845
-
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
-
Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G. 1997. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787-795.
-
(1997)
Int J Cancer
, vol.71
, pp. 787-795
-
-
Linn, S.C.1
Pinedo, H.M.2
Van Ark-Otte, J.3
Van Der Valk, P.4
Hoekman, K.5
Honkoop, A.H.6
Vermorken, J.B.7
Giaccone, G.8
-
105
-
-
17644432403
-
Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint
-
Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ. 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459.
-
(2000)
Genes Dev
, vol.14
, pp. 1448-1459
-
-
Liu, Q.1
Guntuku, S.2
Cui, X.S.3
Matsuoka, S.4
Cortez, D.5
Tamai, K.6
Luo, G.7
Carattini-Rivera, S.8
DeMayo, F.9
Bradley, A.10
Donehower, L.A.11
Elledge, S.J.12
-
106
-
-
0141743327
-
Differential effects of cell cycle regulatory protein p21 on apoptosis and sensitivity to cancer chemotherapy
-
Liu S, Bishop WR, Lin M. 2003. Differential effects of cell cycle regulatory protein p21 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 6:183-195.
-
(2003)
Drug Resist Updat
, vol.6
, pp. 183-195
-
-
Liu, S.1
Bishop, W.R.2
Lin, M.3
-
107
-
-
0025633582
-
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
-
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
-
(1990)
Science
, vol.250
, pp. 1233-1238
-
-
Malkin, D.1
Li, F.P.2
Strong, L.C.3
Fraumeni Jr., J.F.4
Nelson, C.E.5
Kim, D.H.6
Kassel, J.7
Gryka, M.A.8
Bischoff, F.Z.9
Tainsky, M.A.10
-
108
-
-
0034063604
-
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
-
Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG Jr. 2000. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47-54.
-
(2000)
Nat Genet
, vol.25
, pp. 47-54
-
-
Marin, M.C.1
Jost, C.A.2
Brooks, L.A.3
Irwin, M.S.4
O'Nions, J.5
Tidy, J.A.6
James, N.7
McGregor, J.M.8
Harwood, C.A.9
Yulug, I.G.10
Vousden, K.H.11
Allday, M.J.12
Gusterson, B.13
Ikawa, S.14
Hinds, P.W.15
Crook, T.16
Kaelin Jr., W.G.17
-
109
-
-
0032484084
-
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
-
Matsuoka S, Huang M, Elledge SJ. 1998. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893-1897.
-
(1998)
Science
, vol.282
, pp. 1893-1897
-
-
Matsuoka, S.1
Huang, M.2
Elledge, S.J.3
-
110
-
-
0043136753
-
Identification of S-fluorouracil-inducible target genes using cDNA microarray profiling
-
Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ, Johnston PG. 2003. Identification of S-fluorouracil- inducible target genes using cDNA microarray profiling. Cancer Res 63:4602-4606.
-
(2003)
Cancer Res
, vol.63
, pp. 4602-4606
-
-
Maxwell, P.J.1
Longley, D.B.2
Latif, T.3
Boyer, J.4
Allen, W.5
Lynch, M.6
McDermott, U.7
Harkin, D.P.8
Allegra, C.J.9
Johnston, P.G.10
-
111
-
-
0037085271
-
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy
-
Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. 2002. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-5489.
-
(2002)
J Biol Chem
, vol.277
, pp. 5484-5489
-
-
Mayo, L.D.1
Dixon, J.E.2
Durden, D.L.3
Tonks, N.K.4
Donner, D.B.5
-
112
-
-
18644380783
-
Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer
-
McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O'nions J, Young AR, Surentheran T, Breuer J, Millard TP, Lewis CM, Leigh IM, Storey A, Crook T. 2002. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 119:84-90.
-
(2002)
J Invest Dermatol
, vol.119
, pp. 84-90
-
-
McGregor, J.M.1
Harwood, C.A.2
Brooks, L.3
Fisher, S.A.4
Kelly, D.A.5
O'nions, J.6
Young, A.R.7
Surentheran, T.8
Breuer, J.9
Millard, T.P.10
Lewis, C.M.11
Leigh, I.M.12
Storey, A.13
Crook, T.14
-
113
-
-
18344369169
-
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway
-
Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. 2002. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622.
-
(2002)
Oncogene
, vol.21
, pp. 2613-2622
-
-
Mirza, A.1
McGuirk, M.2
Hockenberry, T.N.3
Wu, Q.4
Ashar, H.5
Black, S.6
Wen, S.F.7
Wang, L.8
Kirschmeier, P.9
Bishop, W.R.10
Nielsen, L.L.11
Pickett, C.B.12
Liu, S.13
-
114
-
-
12444252198
-
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression
-
Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier P, Greene JR, Liu S. 2003. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22:3645.
-
(2003)
Oncogene
, vol.22
, pp. 3645
-
-
Mirza, A.1
Wu, Q.2
Wang, L.3
McClanahan, T.4
Bishop, W.R.5
Gheyas, F.6
Ding, W.7
Hutchins, B.8
Hockenberry, T.9
Kirschmeier, P.10
Greene, J.R.11
Liu, S.12
-
115
-
-
0033765491
-
Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis
-
Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. 2000. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055-1063.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4055-1063
-
-
Mitsudomi, T.1
Hamajima, N.2
Ogawa, M.3
Takahashi, T.4
-
117
-
-
0033959744
-
MDM2-master regulator of the p53 tumor suppressor protein
-
Momand J, Wu HH, Dasgupta G. 2000. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15-29.
-
(2000)
Gene
, vol.242
, pp. 15-29
-
-
Momand, J.1
Wu, H.H.2
Dasgupta, G.3
-
118
-
-
0030625476
-
The use of biomarkers to study pathogenesis and mechanisms of cancer: Oesophagus and skin cancer as models
-
Montesano R, Hainaut P, Hall J. 1997. The use of biomarkers to study pathogenesis and mechanisms of cancer: oesophagus and skin cancer as models. IARC Sci Publ 142:291-301.
-
(1997)
IARC Sci Publ
, vol.142
, pp. 291-301
-
-
Montesano, R.1
Hainaut, P.2
Hall, J.3
-
119
-
-
0029564410
-
Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein
-
Moriki T, Takahashi T, Tanioka F, Yamane T, Hara H. 1995. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. Pathol Res Pract 191:1122-1132.
-
(1995)
Pathol Res Pract
, vol.191
, pp. 1122-1132
-
-
Moriki, T.1
Takahashi, T.2
Tanioka, F.3
Yamane, T.4
Hara, H.5
-
120
-
-
0029803281
-
Wild-type p53 negatively regulates the expression of a microtubule-associated protein
-
Murphy M, Hinman A, Levine AJ. 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10:2971-2980.
-
(1996)
Genes Dev
, vol.10
, pp. 2971-2980
-
-
Murphy, M.1
Hinman, A.2
Levine, A.J.3
-
121
-
-
1142263100
-
Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients
-
Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, Torigoe T, Sato N, Watanabe N. 2004. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 95:44-51.
-
(2004)
Cancer Sci
, vol.95
, pp. 44-51
-
-
Nakamura, M.1
Tsuji, N.2
Asanuma, K.3
Kobayashi, D.4
Yagihashi, A.5
Hirata, K.6
Torigoe, T.7
Sato, N.8
Watanabe, N.9
-
122
-
-
0028109125
-
Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants
-
Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV. 1994. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71-77.
-
(1994)
Oncol Res
, vol.6
, pp. 71-77
-
-
Nguyen, K.T.1
Liu, B.2
Ueda, K.3
Gottesman, M.M.4
Pastan, I.5
Chin, K.V.6
-
123
-
-
0031944077
-
Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
-
Nielsen LL, Lipari P, Dell J, Curnani M, Hajian G. 1998. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4:835-846.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 835-846
-
-
Nielsen, L.L.1
Lipari, P.2
Dell, J.3
Curnani, M.4
Hajian, G.5
-
124
-
-
0034141471
-
Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations
-
Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. 2000. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19:370-378.
-
(2000)
EMBO J
, vol.19
, pp. 370-378
-
-
Nikolova, P.V.1
Wong, K.B.2
DeDecker, B.3
Henckel, J.4
Fersht, A.R.5
-
125
-
-
0030865104
-
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
-
O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
-
(1997)
Cancer Res
, vol.57
, pp. 4285-4300
-
-
O'Connor, P.M.1
Jackman, J.2
Bae, I.3
Myers, T.G.4
Fan, S.5
Mutoh, M.6
Scudiero, D.A.7
Monks, A.8
Sausville, E.A.9
Weinstein, J.N.10
Friend, S.11
Fornace Jr., A.J.12
Kohn, K.W.13
-
126
-
-
0342657718
-
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
-
Olie RA, Simoes-Wust AP, Banmann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. 2000. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805-2809.
-
(2000)
Cancer Res
, vol.60
, pp. 2805-2809
-
-
Olie, R.A.1
Simoes-Wust, A.P.2
Banmann, B.3
Leech, S.H.4
Fabbro, D.5
Stahel, R.A.6
Zangemeister-Wittke, U.7
-
127
-
-
0036258111
-
The IARC TP53 database: New online mutation analysis and recommendations to users
-
Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainant P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614.
-
(2002)
Hum Mutat
, vol.19
, pp. 607-614
-
-
Olivier, M.1
Eeles, R.2
Hollstein, M.3
Khan, M.A.4
Harris, C.C.5
Hainant, P.6
-
128
-
-
0030448760
-
Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide
-
Ostermeyer AG, Runko E, Winkfield B, Ahn B, Moll UM. 1996. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A 93:15190-15194.
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, pp. 15190-15194
-
-
Ostermeyer, A.G.1
Runko, E.2
Winkfield, B.3
Ahn, B.4
Moll, U.M.5
-
129
-
-
0025748539
-
p53 mutation in hepatocellular carcinoma after aflatoxin exposure
-
Ozturk M. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338:1356-1359.
-
(1991)
Lancet
, vol.338
, pp. 1356-1359
-
-
Ozturk, M.1
-
130
-
-
0037152688
-
Association of p53 codon 72 polymorphism with advanced lung cancer: The Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes
-
Papadakis ED, Soulitzis N, Spandidos DA. 2002. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87:1013-1018.
-
(2002)
Br J Cancer
, vol.87
, pp. 1013-1018
-
-
Papadakis, E.D.1
Soulitzis, N.2
Spandidos, D.A.3
-
131
-
-
0035110767
-
The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma
-
Park YB, Kim HS, Oh JH, Lee SH. 2001. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24:307-310.
-
(2001)
Int Orthop
, vol.24
, pp. 307-310
-
-
Park, Y.B.1
Kim, H.S.2
Oh, J.H.3
Lee, S.H.4
-
132
-
-
0028246289
-
Light-generated oligonucleotide arrays for rapid DNA sequence analysis
-
Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP 1994. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 91:5022-5026.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 5022-5026
-
-
Pease, A.C.1
Solas, D.2
Sullivan, E.J.3
Cronin, M.T.4
Holmes, C.P.5
Fodor, S.P.6
-
133
-
-
0035876039
-
Phase I and pharmacokinetic study of the novel MDK1 and MKP1 inhibitor biricodar administered alone and in combination with doxorubicin
-
Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PH, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ. 2001. Phase I and pharmacokinetic study of the novel MDK1 and MKP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130-3141.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3130-3141
-
-
Peck, R.A.1
Hewett, J.2
Harding, M.W.3
Wang, Y.M.4
Chaturvedi, P.H.5
Bhatnagar, A.6
Ziessman, H.7
Atkins, F.8
Hawkins, M.J.9
-
134
-
-
3042552397
-
Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo
-
Feb 4 [Epub ahead of print]
-
Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, Daidone MG, Zimino F, Zaffaroni N. 2004. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis Feb 4 [Epub ahead of print].
-
(2004)
Carcinogenesis
-
-
Pennati, M.1
Binda, M.2
De Cesare, M.3
Pratesi, G.4
Folini, M.5
Citti, L.6
Daidone, M.G.7
Zimino, F.8
Zaffaroni, N.9
-
135
-
-
0031873441
-
Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines
-
8
-
Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI. 1998. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77:913-91.8.
-
(1998)
Int J Cancer
, vol.77
, pp. 913-991
-
-
Pestell, K.E.1
Medlow, C.J.2
Titley, J.C.3
Kelland, L.R.4
Walton, M.I.5
-
136
-
-
0028365987
-
Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity
-
Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane DP, Preece PE, Andreotti PE. 1994. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 199:264-270.
-
(1994)
Biochem Biophys Res Commun
, vol.199
, pp. 264-270
-
-
Petty, R.D.1
Cree, I.A.2
Sutherland, L.A.3
Hunter, E.M.4
Lane, D.P.5
Preece, P.E.6
Andreotti, P.E.7
-
137
-
-
0033851133
-
Does p53 status influence tumor response to anticancer therapies?
-
Pirollo KF, Bouker KB, Chang EH. 2001. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11:419-432.
-
(2001)
Anticancer Drugs
, vol.11
, pp. 419-432
-
-
Pirollo, K.F.1
Bouker, K.B.2
Chang, E.H.3
-
138
-
-
0037445965
-
Molecular targeting and pharmacogenomics in the management of advanced bladder cancer
-
Raghavan D. 2003. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97:2083-2089.
-
(2003)
Cancer
, vol.97
, pp. 2083-2089
-
-
Raghavan, D.1
-
139
-
-
0034796867
-
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer
-
Reles A, Wen WH, Schmider A, Gee C, Rumebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF. 2001. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7:2984-2997.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2984-2997
-
-
Reles, A.1
Wen, W.H.2
Schmider, A.3
Gee, C.4
Rumebaum, I.B.5
Kilian, U.6
Jones, L.A.7
El-Naggar, A.8
Minguillon, C.9
Schonborn, I.10
Reich, O.11
Kreienberg, R.12
Lichtenegger, W.13
Press, M.F.14
-
140
-
-
13344249778
-
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
-
Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F. 1996. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693.
-
(1996)
Cancer Res
, vol.56
, pp. 689-693
-
-
Righetti, S.C.1
Della Torre, G.2
Pilotti, S.3
Menard, S.4
Ottone, F.5
Colnaghi, M.I.6
Pierotti, M.A.7
Lavarino, C.8
Cornarotti, M.9
Oriana, S.10
Bohm, S.11
Bresciani, G.L.12
Spatti, G.13
Zunino, F.14
-
141
-
-
3042672714
-
Validation of tissue microarray technology in ovarian carcinoma
-
Apr 9 [Epub ahead of print]
-
Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. 2004. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol Apr 9 [Epub ahead of print].
-
(2004)
Mod Pathol
-
-
Rosen, D.G.1
Huang, X.2
Deavers, M.T.3
Malpica, A.4
Silva, E.G.5
Liu, J.6
-
142
-
-
0033158714
-
Analysis of Bcl-2, Bax and Survivin genes in uterine cancer
-
Saitoh Y, Yaginuma Y, Ishikawa M. 1999. Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol 15:137-141.
-
(1999)
Int J Oncol
, vol.15
, pp. 137-141
-
-
Saitoh, Y.1
Yaginuma, Y.2
Ishikawa, M.3
-
143
-
-
0033199892
-
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
-
Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. 1999. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59:4375-4382.
-
(1999)
Cancer Res
, vol.59
, pp. 4375-4382
-
-
Sarkaria, J.N.1
Busby, E.C.2
Tibbetts, R.S.3
Roos, P.4
Taya, Y.5
Karnitz, L.M.6
Abraham, R.T.7
-
144
-
-
0033214798
-
Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma
-
Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, Kamazawa S, Terakawa N. 1999. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 86:1307-1313.
-
(1999)
Cancer
, vol.86
, pp. 1307-1313
-
-
Sato, S.1
Kigawa, J.2
Minagawa, Y.3
Okada, M.4
Shimada, M.5
Takahashi, M.6
Kamazawa, S.7
Terakawa, N.8
-
145
-
-
0029057336
-
A single ataxia telangiectasia gene with a product similar to PI-3 kinase
-
Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, et al. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-1753.
-
(1995)
Science
, vol.268
, pp. 1749-1753
-
-
Savitsky, K.1
Bar-Shira, A.2
Gilad, S.3
Rotman, G.4
Ziv, Y.5
Vanagaite, L.6
Tagle, D.A.7
Smith, S.8
Uziel, T.9
Sfez, S.10
-
146
-
-
0038751860
-
p53 downstream targets and chemosensitivity
-
Sax JK, El-Deiry WS. 2003. p53 downstream targets and chemosensitivity. Cell Death Differ 10:413-417.
-
(2003)
Cell Death Differ
, vol.10
, pp. 413-417
-
-
Sax, J.K.1
El-Deiry, W.S.2
-
147
-
-
85006263913
-
BID regulation by p53 contributes to chemosensitivity
-
Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. 2002. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4:842-849.
-
(2002)
Nat Cell Biol
, vol.4
, pp. 842-849
-
-
Sax, J.K.1
Fei, P.2
Murphy, M.E.3
Bernhard, E.4
Korsmeyer, S.J.5
El-Deiry, W.S.6
-
148
-
-
0031780665
-
Ubiquitin, E6-AP, and their role in p53 inactivation
-
Scheffner M. 1998. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 78:129-139.
-
(1998)
Pharmacol Ther
, vol.78
, pp. 129-139
-
-
Scheffner, M.1
-
149
-
-
0029748326
-
Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes
-
Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW. 1996. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 93:10614-10619.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 10614-10619
-
-
Schena, M.1
Shalon, D.2
Heller, R.3
Chai, A.4
Brown, P.O.5
Davis, R.W.6
-
150
-
-
0034088857
-
A gene expression database for the molecular pharmacology of cancer
-
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kolm KW, Reinhold WC, Myers TG, Andrews DT, Sendiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. 2000. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244.
-
(2000)
Nat Genet
, vol.24
, pp. 236-244
-
-
Scherf, U.1
Ross, D.T.2
Waltham, M.3
Smith, L.H.4
Lee, J.K.5
Tanabe, L.6
Kolm, K.W.7
Reinhold, W.C.8
Myers, T.G.9
Andrews, D.T.10
Sendiero, D.A.11
Eisen, M.B.12
Sausville, E.A.13
Pommier, Y.14
Botstein, D.15
Brown, P.O.16
Weinstein, J.N.17
-
151
-
-
0035863302
-
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
-
Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH. 2001. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 19:448-457.
-
(2001)
J Clin Oncol
, vol.19
, pp. 448-457
-
-
Schiller, J.H.1
Adak, S.2
Feins, R.H.3
Keller, S.M.4
Fry, W.A.5
Livingston, R.B.6
Hammond, M.E.7
Wolf, B.8
Sabatini, L.9
Jett, J.10
Kohman, L.11
Johnson, D.H.12
-
152
-
-
0033569423
-
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
-
Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670-2677.
-
(1999)
Genes Dev
, vol.13
, pp. 2670-2677
-
-
Schmitt, C.A.1
McCurrach, M.E.2
De Stanchina, E.3
Wallace-Brodeur, R.R.4
Lowe, S.W.5
-
153
-
-
0034480069
-
Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: Correlation with the response to therapy and the expression of MDR1 and LRP
-
Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M. 2000a. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 20:4373-4377.
-
(2000)
Anticancer Res
, vol.20
, pp. 4373-4377
-
-
Schneider, J.1
Lucas, R.2
Sanchez, J.3
Ruibal, A.4
Tejerina, A.5
Martin, M.6
-
154
-
-
0033875562
-
P53 mutational status improves estimation of prognosis in patients with
-
Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Decker K, Dittler HJ, Fink U, Siewert JR. 2000b. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 6:3153-3158.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3153-3158
-
-
Schneider, P.M.1
Stoeltzing, O.2
Roth, J.A.3
Hoelscher, A.H.4
Wegerer, S.5
Mizumoto, S.6
Decker, K.7
Dittler, H.J.8
Fink, U.9
Siewert, J.R.10
-
155
-
-
1842457693
-
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer
-
Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. 2004. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22:1014-1024.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1014-1024
-
-
Shariat, S.F.1
Tokunaga, H.2
Zhou, J.3
Kim, J.4
Ayala, G.E.5
Benedict, W.F.6
Lerner, S.P.7
-
156
-
-
0035487104
-
The INK4a/ARF network in tumour suppression
-
Sherr CJ. 2001. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731-737.
-
(2001)
Nat Rev Mol Cell Biol
, vol.2
, pp. 731-737
-
-
Sherr, C.J.1
-
157
-
-
0035969963
-
An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7
-
Shin S, Sung B-J, Cho Y-S, Kim H-J, Ha N-C, Hwang J-I, Chung C-W, Jung Y-K, Oh B-H. 2001. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117-1123.
-
(2001)
Biochemistry
, vol.40
, pp. 1117-1123
-
-
Shin, S.1
Sung, B.-J.2
Cho, Y.-S.3
Kim, H.-J.4
Ha, N.-C.5
Hwang, J.-I.6
Chung, C.-W.7
Jung, Y.-K.8
Oh, B.-H.9
-
158
-
-
0030058617
-
The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
-
Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J. 1996. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 173-182
-
-
Sjogren, S.1
Inganas, M.2
Norberg, T.3
Lindgren, A.4
Nordgren, H.5
Holmberg, L.6
Bergh, J.7
-
159
-
-
0034100053
-
p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients
-
Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A. 2000. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 6:1031-1037.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1031-1037
-
-
Skaug, V.1
Ryberg, D.2
Kure, E.H.3
Arab, M.O.4
Stangeland, L.5
Myking, A.O.6
Haugen, A.7
-
160
-
-
0034168495
-
Tumor suppressor p53: Regulation and function
-
Somasundaram K, El-Deiry WS. 2000. Tumor suppressor p53: regulation and function. Frontier Biosci 5:424-437.
-
(2000)
Frontier Biosci
, vol.5
, pp. 424-437
-
-
Somasundaram, K.1
El-Deiry, W.S.2
-
161
-
-
0033931447
-
The p53 tumor suppressor gene: From molecular biology to clinical investigation
-
Soussi T. 2000. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 910:121-137.
-
(2000)
Ann N Y Acad Sci
, vol.910
, pp. 121-137
-
-
Soussi, T.1
-
162
-
-
0035751937
-
Assessing TP53 status in human tumours to evaluate clinical outcome
-
Soussi T, Beroud C. 2001. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233-240.
-
(2001)
Nat Rev Cancer
, vol.1
, pp. 233-240
-
-
Soussi, T.1
Beroud, C.2
-
163
-
-
17944380542
-
Role of p53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis
-
Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP. 2001. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18:705-719.
-
(2001)
Eur Respir J
, vol.18
, pp. 705-719
-
-
Steels, E.1
Paesmans, M.2
Berghmans, T.3
Branle, F.4
Lemaitre, F.5
Mascaux, C.6
Meert, A.P.7
Vallot, F.8
Lafitte, J.J.9
Sculier, J.P.10
-
164
-
-
0029587415
-
The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins
-
Strauss BE, Haas M. 1995a. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun 217:333-340.
-
(1995)
Biochem Biophys Res Commun
, vol.217
, pp. 333-340
-
-
Strauss, B.E.1
Haas, M.2
-
165
-
-
0029619819
-
The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53
-
Strauss BE, Shivakumar C, Deb SP, Deb S, Haas M. 1995b. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun 217:825-831.
-
(1995)
Biochem Biophys Res Commun
, vol.217
, pp. 825-831
-
-
Strauss, B.E.1
Shivakumar, C.2
Deb, S.P.3
Deb, S.4
Haas, M.5
-
166
-
-
0033953099
-
UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation
-
Sugiyama K, Shimizu M, Akiyama T, Tamaoki T, Yamaguchi K, Takahashi R, Eastman A, Akinaga S. 2000. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 85:703-709.
-
(2000)
Int J Cancer
, vol.85
, pp. 703-709
-
-
Sugiyama, K.1
Shimizu, M.2
Akiyama, T.3
Tamaoki, T.4
Yamaguchi, K.5
Takahashi, R.6
Eastman, A.7
Akinaga, S.8
-
167
-
-
85047695017
-
Concomitant inactivation of p53 and Chk2 in breast cancer
-
Sullivan A, Yuille M, Repellin C, Reddy A, Reelfs O, Bell A, Dunne B, Gusterson BA, Osin P, Farrell PJ, Yulug I, Evans A, Ozcelik T, Gasco M, Crook T. 2002. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21:1316-1324.
-
(2002)
Oncogene
, vol.21
, pp. 1316-1324
-
-
Sullivan, A.1
Yuille, M.2
Repellin, C.3
Reddy, A.4
Reelfs, O.5
Bell, A.6
Dunne, B.7
Gusterson, B.A.8
Osin, P.9
Farrell, P.J.10
Yulug, I.11
Evans, A.12
Ozcelik, T.13
Gasco, M.14
Crook, T.15
-
168
-
-
0031749970
-
The expression of drug resistance gene products during the progression of human prostate cancer
-
Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. 1998. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393-1403.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 1393-1403
-
-
Sullivan, G.F.1
Amenta, P.S.2
Villanueva, J.D.3
Alvarez, C.J.4
Yang, J.M.5
Hait, W.N.6
-
169
-
-
0034063577
-
Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells
-
Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN. 2000. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105:1261-1267.
-
(2000)
J Clin Invest
, vol.105
, pp. 1261-1267
-
-
Sullivan, G.F.1
Yang, J.M.2
Vassil, A.3
Yang, J.4
Bash-Babula, J.5
Hait, W.N.6
-
170
-
-
0034783885
-
A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line
-
Supino R, Perego P, Gatti L, Caserini C, Leonetti C, Colantuono M, Zuco V, Carenini N, Zupi G, Zunino F. 2001. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. Eur J Cancer 37:2247-2256.
-
(2001)
Eur J Cancer
, vol.37
, pp. 2247-2256
-
-
Supino, R.1
Perego, P.2
Gatti, L.3
Caserini, C.4
Leonetti, C.5
Colantuono, M.6
Zuco, V.7
Carenini, N.8
Zupi, G.9
Zunino, F.10
-
171
-
-
0031890636
-
Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma
-
Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. 1998. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 89:221-227.
-
(1998)
Jpn J Cancer Res
, vol.89
, pp. 221-227
-
-
Suzuki, A.1
Toi, M.2
Yamamoto, Y.3
Saji, S.4
Muta, M.5
Tominaga, T.6
-
172
-
-
0036490983
-
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation
-
Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, el-Deiry WS. 2002. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther 1:177-186.
-
(2002)
Cancer Biol Ther
, vol.1
, pp. 177-186
-
-
Takimoto, R.1
MacLachlan, T.K.2
Dicker, D.T.3
Niitsu, Y.4
Mori, T.5
El-Deiry, W.S.6
-
173
-
-
0033980409
-
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
-
Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. 2000. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 127-134
-
-
Tanaka, K.1
Iwamoto, S.2
Gon, G.3
Nohara, T.4
Iwamoto, M.5
Tanigawa, N.6
-
174
-
-
0037031210
-
Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein
-
Tang J, Chu G. 2002. Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein. DNA Repair (Amst) 1:601-616.
-
(2002)
DNA Repair (Amst)
, vol.1
, pp. 601-616
-
-
Tang, J.1
Chu, G.2
-
175
-
-
0036118391
-
Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways
-
Tian H, Faje AT, Lee SL, Jorgensen TJ. 2002. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. Neoplasia 4:171-180.
-
(2002)
Neoplasia
, vol.4
, pp. 171-180
-
-
Tian, H.1
Faje, A.T.2
Lee, S.L.3
Jorgensen, T.J.4
-
176
-
-
0033555260
-
A role for ATR in the DNA damage-induced phosphorylation of p53
-
Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Java Y, Prives C, Abraham RT. 1999. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13:152-157.
-
(1999)
Genes Dev
, vol.13
, pp. 152-157
-
-
Tibbetts, R.S.1
Brumbaugh, K.M.2
Williams, J.M.3
Sarkaria, J.N.4
Cliby, W.A.5
Shieh, S.Y.6
Java, Y.7
Prives, C.8
Abraham, R.T.9
-
177
-
-
0033611560
-
Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma
-
Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J. 1999. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18:1007-1014.
-
(1999)
Oncogene
, vol.18
, pp. 1007-1014
-
-
Tomizawa, Y.1
Kohno, T.2
Fujita, T.3
Kiyama, M.4
Saito, R.5
Noguchi, M.6
Matsuno, Y.7
Hirohashi, S.8
Yamaguchi, N.9
Nakajima, T.10
Yokota, J.11
-
178
-
-
0037117504
-
Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene
-
Tonisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H, Meiel A, Hainaut P, Metspalu A. 2002. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci USA 99:5503-5508.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 5503-5508
-
-
Tonisson, N.1
Zernant, J.2
Kurg, A.3
Pavel, H.4
Slavin, G.5
Roomere, H.6
Meiel, A.7
Hainaut, P.8
Metspalu, A.9
-
179
-
-
0028215974
-
Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer
-
Tornaletti S, Pfeifer GP. 1994. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science 263:1436-1438.
-
(1994)
Science
, vol.263
, pp. 1436-1438
-
-
Tornaletti, S.1
Pfeifer, G.P.2
-
180
-
-
0037325522
-
Modulation of multidrug resistance-associated protein 1 (MRF1) by p53 mutant in Saos-2 cells
-
Tsang WP, Chan SF, Fung KP, Kong SK, Kwok TT. 2003. Modulation of multidrug resistance-associated protein 1 (MRF1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol 51:161-106.
-
(2003)
Cancer Chemother Pharmacol
, vol.51
, pp. 161-106
-
-
Tsang, W.P.1
Chan, S.F.2
Fung, K.P.3
Kong, S.K.4
Kwok, T.T.5
-
181
-
-
0034751004
-
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer
-
Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowiez JF, Van Der Kwast TH, Schroder FH, Mickisch CH. 2001. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 165:130-135.
-
(2001)
J Urol
, vol.165
, pp. 130-135
-
-
Van Brussel, J.P.1
Jan Van Steenbrugge, G.2
Van Krimpen, C.3
Bogdanowiez, J.F.4
Van Der Kwast, T.H.5
Schroder, F.H.6
Mickisch, C.H.7
-
183
-
-
10744221485
-
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
-
Vassilev LT, Vu RT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Lin EA. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
-
(2004)
Science
, vol.303
, pp. 844-848
-
-
Vassilev, L.T.1
Vu, R.T.2
Graves, B.3
Carvajal, D.4
Podlaski, F.5
Filipovic, Z.6
Kong, N.7
Kammlott, U.8
Lukacs, C.9
Klein, C.10
Fotouhi, N.11
Lin, E.A.12
-
184
-
-
0036533524
-
-
Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T. 2002. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. 98:498-504.
-
(2002)
Resistance of Colon Cancer Cells to Long-Term 5-Fluorouracil Exposure is Correlated to the Relative Level of Bcl-2 and Bcl-X(L) in Addition to Bax and p53 Status
, vol.98
, pp. 498-504
-
-
Violette, S.1
Poulain, L.2
Dussaulx, E.3
Pepin, D.4
Faussat, A.M.5
Chambaz, J.6
Lacorte, J.M.7
Staedel, C.8
Lesuffleur, T.9
-
185
-
-
0027434831
-
Absence of p53 gene mutations in primary neuroblastomas
-
Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gros P. 1993. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53:5269-5273.
-
(1993)
Cancer Res
, vol.53
, pp. 5269-5273
-
-
Vogan, K.1
Bernstein, M.2
Leclerc, J.M.3
Brisson, L.4
Brossard, J.5
Brodeur, G.M.6
Pelletier, J.7
Gros, P.8
-
187
-
-
0036189873
-
p53 gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer
-
Vogt U, Zaczek A, Klinke F, Granetzny A, Bielawski K, Falkiewicz B. 2002. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J Cancer Res Clin Oncol 128:141-147.
-
(2002)
J Cancer Res Clin Oncol
, vol.128
, pp. 141-147
-
-
Vogt, U.1
Zaczek, A.2
Klinke, F.3
Granetzny, A.4
Bielawski, K.5
Falkiewicz, B.6
-
189
-
-
0030026934
-
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
-
Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Deniers GW, Galloway DA. 1996. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79.
-
(1996)
Nat Med
, vol.2
, pp. 72-79
-
-
Wahl, A.F.1
Donaldson, K.L.2
Fairchild, C.3
Lee, F.Y.4
Foster, S.A.5
Deniers, G.W.6
Galloway, D.A.7
-
190
-
-
0035195557
-
The evolution of diverse biological responses to DNA damage: Insights from yeast and p53
-
Wahl GM, Carr AM. 2001. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3:E277-286.
-
(2001)
Nat Cell Biol
, vol.3
-
-
Wahl, G.M.1
Carr, A.M.2
-
191
-
-
0345735895
-
The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2
-
Wang EJ, Johnson WW. 2003a. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy 49:303-308.
-
(2003)
Chemotherapy
, vol.49
, pp. 303-308
-
-
Wang, E.J.1
Johnson, W.W.2
-
192
-
-
1342332342
-
Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: In vitro and in vivo activities and mechanisms
-
Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. 2003b. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: In vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 1002:217-235.
-
(2003)
Ann N Y Acad Sci
, vol.1002
, pp. 217-235
-
-
Wang, H.1
Oliver, P.2
Zhang, Z.3
Agrawal, S.4
Zhang, R.5
-
193
-
-
0035941214
-
Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches
-
Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene JR, Wang Y, Pickett CB, Liu S. 2001. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 276:43604-43610.
-
(2001)
J Biol Chem
, vol.276
, pp. 43604-43610
-
-
Wang, L.1
Wu, Q.2
Qiu, P.3
Mirza, A.4
McGuirk, M.5
Kirschmeier, P.6
Greene, J.R.7
Wang, Y.8
Pickett, C.B.9
Liu, S.10
-
194
-
-
0032535308
-
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53
-
Wang Q, Beck WT. 1998. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58:5762-5769.
-
(1998)
Cancer Res
, vol.58
, pp. 5762-5769
-
-
Wang, Q.1
Beck, W.T.2
-
195
-
-
12144287074
-
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance
-
Wang S, Folkes A, Chuckowree I, Cockcroft X, Sohal S, Miller W, Milton J, Wren SP, Vieker N, Depledge P, Scott J, Smith L, Jones H, Mistry P, Faint R, Thompson D, Cocks S. 2004a. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance. J Med Chem 47:1329-1338.
-
(2004)
J Med Chem
, vol.47
, pp. 1329-1338
-
-
Wang, S.1
Folkes, A.2
Chuckowree, I.3
Cockcroft, X.4
Sohal, S.5
Miller, W.6
Milton, J.7
Wren, S.P.8
Vieker, N.9
Depledge, P.10
Scott, J.11
Smith, L.12
Jones, H.13
Mistry, P.14
Faint, R.15
Thompson, D.16
Cocks, S.17
-
196
-
-
1542359077
-
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
-
Wang Y, Heiland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Trope CG, Borresen-Dale AL, Kristensen GB. 2004b. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 90:678-685.
-
(2004)
Br J Cancer
, vol.90
, pp. 678-685
-
-
Wang, Y.1
Heiland, A.2
Holm, R.3
Skomedal, H.4
Abeler, V.M.5
Danielsen, H.E.6
Trope, C.G.7
Borresen-Dale, A.L.8
Kristensen, G.B.9
-
197
-
-
0034657333
-
Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis
-
Wen WH, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, Press MF. 2000. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 60:2716-2722.
-
(2000)
Cancer Res
, vol.60
, pp. 2716-2722
-
-
Wen, W.H.1
Bernstein, L.2
Lescallett, J.3
Beazer-Barclay, Y.4
Sullivan-Halley, J.5
White, M.6
Press, M.F.7
-
198
-
-
0030754662
-
Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: A meta-analysis
-
Weston A, Godbold JH. 1997. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105:919-926.
-
(1997)
Environ Health Perspect
, vol.105
, pp. 919-926
-
-
Weston, A.1
Godbold, J.H.2
-
199
-
-
0036300312
-
7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines
-
Xiao HH, Makeyev Y, Butler J, Vikrani B, Franklin WA. 2002. 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. Radiat Res 158:84-93.
-
(2002)
Radiat Res
, vol.158
, pp. 84-93
-
-
Xiao, H.H.1
Makeyev, Y.2
Butler, J.3
Vikrani, B.4
Franklin, W.A.5
-
200
-
-
6444245364
-
p53 latency-out of the blind alley
-
Yakovleva T, Pramanik A, Terenius L, Ekstrom TJ, Bakalkin G. 2002. p53 latency-out of the blind alley. Trends Biochem Sci 27:612-618.
-
(2002)
Trends Biochem Sci
, vol.27
, pp. 612-618
-
-
Yakovleva, T.1
Pramanik, A.2
Terenius, L.3
Ekstrom, T.J.4
Bakalkin, G.5
-
201
-
-
85010788247
-
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
-
Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H. 2004. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:R24-30.
-
(2004)
Breast Cancer Res
, vol.6
-
-
Yamashita, H.1
Nishio, M.2
Toyama, T.3
Sugiura, H.4
Zhang, Z.5
Kobayashi, S.6
Iwase, H.7
-
202
-
-
0029962567
-
Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells
-
Yang B, Eshleman JR, Berger NA, Markowitz SD. 1996. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2:1649-1657.
-
(1996)
Clin Cancer Res
, vol.2
, pp. 1649-1657
-
-
Yang, B.1
Eshleman, J.R.2
Berger, N.A.3
Markowitz, S.D.4
-
203
-
-
16044371194
-
Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase
-
Yao SL, Akhtar AJ, McKenna KA, Bedi GG, Sidransky D, Mabry M, Ravi R, Collector MI, Jones RJ, Sharkis SJ, Fuchs EJ, Bedi A. 1996. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 2:1140-1143.
-
(1996)
Nat Med
, vol.2
, pp. 1140-1143
-
-
Yao, S.L.1
Akhtar, A.J.2
McKenna, K.A.3
Bedi, G.G.4
Sidransky, D.5
Mabry, M.6
Ravi, R.7
Collector, M.I.8
Jones, R.J.9
Sharkis, S.J.10
Fuchs, E.J.11
Bedi, A.12
-
204
-
-
0037108873
-
UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1
-
Yu Q, La Rose J, Zhang H, Takemura H, Kolm KW, Pommier Y. 2002. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 62:5743-5748.
-
(2002)
Cancer Res
, vol.62
, pp. 5743-5748
-
-
Yu, Q.1
La Rose, J.2
Zhang, H.3
Takemura, H.4
Kolm, K.W.5
Pommier, Y.6
-
205
-
-
0036693488
-
Expression of the anti-apoptotic gene survivin correlates with Taxol resistance in human ovarian cancer
-
Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG. 2002. Expression of the anti-apoptotic gene survivin correlates with Taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406-1412.
-
(2002)
Cell Mol Life Sci
, vol.59
, pp. 1406-1412
-
-
Zaffaroni, N.1
Pennati, M.2
Colella, G.3
Perego, P.4
Supino, R.5
Gatti, L.6
Pilotti, S.7
Zunino, F.8
Daidone, M.G.9
-
206
-
-
0032568221
-
The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
-
Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. 1998. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16:1617-1624.
-
(1998)
Oncogene
, vol.16
, pp. 1617-1624
-
-
Zhang, C.C.1
Yang, J.M.2
White, E.3
Murphy, M.4
Levine, A.5
Hait, W.N.6
-
207
-
-
0033178994
-
DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule- associated protein 4
-
Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN. 1999. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule- associated protein 4. Cancer Res 59:3663-3670.
-
(1999)
Cancer Res
, vol.59
, pp. 3663-3670
-
-
Zhang, C.C.1
Yang, J.M.2
Bash-Babula, J.3
White, E.4
Murphy, M.5
Levine, A.J.6
Hait, W.N.7
-
208
-
-
0141927384
-
Tissue microarray study for classification of breast tumors
-
Zhang DH, Salto-Tellez M, Chiu LL, Shen L, Koay ES. 2003a. Tissue microarray study for classification of breast tumors. Life Sci 73:3189-3199.
-
(2003)
Life Sci
, vol.73
, pp. 3189-3199
-
-
Zhang, D.H.1
Salto-Tellez, M.2
Chiu, L.L.3
Shen, L.4
Koay, E.S.5
-
209
-
-
0037942897
-
Antisense oligonucleotide inhibitors of MDM2 oncogene expression
-
Zhang R, Wang H. 2003b. Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Methods Mol Med 85:205-222.
-
(2003)
Methods Mol Med
, vol.85
, pp. 205-222
-
-
Zhang, R.1
Wang, H.2
-
210
-
-
1642377946
-
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models
-
Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R. 2004. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 10:1263-1273.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 1263-1273
-
-
Zhang, Z.1
Wang, H.2
Prasad, G.3
Li, M.4
Yu, D.5
Bonner, J.A.6
Agrawal, S.7
Zhang, R.8
-
211
-
-
0141919562
-
PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells
-
Zhou M, Gu L, Findley HW, Jiang R, Woods WG. 2003. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 63:6357-6362.
-
(2003)
Cancer Res
, vol.63
, pp. 6357-6362
-
-
Zhou, M.1
Gu, L.2
Findley, H.W.3
Jiang, R.4
Woods, W.G.5
-
212
-
-
1842789760
-
Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: A systematic analysis of primary and metastatic tumor tissue
-
Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. 2004. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651-655.
-
(2004)
Urology
, vol.63
, pp. 651-655
-
-
Zigeuner, R.1
Ratschek, M.2
Rehak, P.3
Schips, L.4
Langner, C.5
|